— Presentation on November 11, 2015, at 2:00 p.m. MT —
BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 2, 2015--
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing desensitization treatments for food allergies, today
announced that it will present at the 2015 Credit Suisse Healthcare
Investor Conference.
About the Presentation
-
Wednesday, November 11, 2015, at 2:00 p.m. Mountain Time
-
The live audio webcast of the presentation can be accessed from the
Investor Relations section of the company’s website at www.aimmune.com.
-
A replay will be available for 14 days following the presentation.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., founded in 2011 as Allergen Research
Corporation (ARC), is a clinical-stage biopharmaceutical company
developing treatments for peanut allergy and other food allergies.
Aimmune Therapeutics’ characterized oral desensitization immunotherapy
(CODIT™) system, an approach to oral immunotherapy (OIT), uses
rigorously characterized product candidates with gradual, controlled
up-dosing protocols to achieve clinically meaningful desensitization to
food allergens. Aimmune Therapeutics recently completed a Phase 2 study
of its lead product, AR101, a complex mixture of naturally occurring
proteins and pharmaceutical-grade ingredients for the treatment of
peanut allergy, one of the most common food allergies. For more
information, please see www.aimmune.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151102005628/en/
Source: Aimmune Therapeutics, Inc.
Investors
Aimmune Therapeutics, Inc.
Amy Figueroa, 650-352-1039
investorrelations@aimmune.com
or
Media
Edelman
Amanda
Breeding, 415-229-7649
amanda.breeding@edelman.com
